These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 18633105)
21. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation. Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198 [TBL] [Abstract][Full Text] [Related]
22. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140 [TBL] [Abstract][Full Text] [Related]
23. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Barth RN; Janus CA; Lillesand CA; Radke NA; Pirsch JD; Becker BN; Fernandez LA; Thomas Chin L; Becker YT; Odorico JS; D'Alessandro AM; Sollinger HW; Knechtle SJ Transpl Int; 2006 Nov; 19(11):885-92. PubMed ID: 17018123 [TBL] [Abstract][Full Text] [Related]
24. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Margreiter R; Klempnauer J; Neuhaus P; Muehlbacher F; Boesmueller C; Calne RY Am J Transplant; 2008 Jul; 8(7):1480-5. PubMed ID: 18510632 [TBL] [Abstract][Full Text] [Related]